GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19)

Inclusion Criteria: * Age 18 years or older * Able to provide consent * Able and willing to comply with study procedures * Diagnosis of PCR confirmed SARS-CoV-2 * Enrollment within 72 of hospitalization * WHO COVID-19 classification level 3 or 4 Exclusion Criteria: * Pregnant or lactating * Need for mechanical ventilation, non-invasive ventilation (NIV), or high-flow O2 (≥60%) via face mask * Calculated GFR \< 60 (Cockcroft-Gault) * Meets treatment algorithm criteria for treatment with a non-study immune modulator * Pre-study or planned treatment with a non-study immune modulator * Participation in a COVID-19 clinical trial that includes prescription of a drug with anti-cytokine activity * Status post transplantation of an organ, bone marrow, or body part * Treatment within the past 60 days with a chemotherapeutic agent * Diagnosis of leukemia or lymphoma * WHO COVID-19 classification level of 5 or greater * Unable to take oral medication * Grade 3 or greater laboratory abnormalities as characterized by CTCAE v5